C1q is the first component of the classical complement pathway. Both clinically validated in-house ELISA assays as well as commercial ELISA kits are used for detection of anti-C1q antibodies. Anti-C1q autoantibodies can be detected in a wide range of autoimmune diseases and are highly sensitive for hypocomplementemic uticarial vasculitis. In SLE, anti-C1q are strongly associated with proliferative lupus nephritis, and their absence carries a negative predictive value for development of lupus nephritis of close to 100%. Anti-C1q in combination with anti-dsDNA and low complement has the strongest serological association with renal involvement. The anti-C1q titers correlate with global disease activity scores in patients with renal involvement, and higher titers seem to precede renal flares. After the successful treatment of a renal flare, anti-C1q has the tendency to decrease or even become undetectable. The main obstacle to the inclusion of anti-C1q in the classification criteria and clinical management of SLE is the lack of standardized laboratory assays.
AgnelloVKofflerDEisenbergJWWinchesterRJKunkelHG. C1q precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: Characterization of high and low molecular weight types. J Exp Med1971; 134: 228–241.
12.
AntesUHeinzHPLoosM. Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum1988; 31: 457–464.
13.
UwatokoSMannikM. Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q. J Clin Invest1988; 82: 816–824.
14.
UwatokoSAotsukaSOkawaM. Characterization of C1q-binding IgG complexes in systemic lupus erythematosus. Clin Immunol Immunopathol1984; 30: 104–116.
15.
MahlerMvan SchaarenburgRATrouwLA. Anti-C1q autoantibodies, novel tests, and clinical consequences. Front Immunol2013; 4: 117–117.
16.
DahaNABandaNKRoosA. Complement activation by (auto-) antibodies. Mol Immunol2011; 48: 1656–1665.
17.
CooperNR. The classical complement pathway: Activation and regulation of the first complement component. Adv Immunol1985; 37: 151–216.
18.
Kohro-KawataJWenerMHMannikM. The effect of high salt concentration on detection of serum immune complexes and autoantibodies to C1q in patients with systemic lupus erythematosus. J Rheumatol2002; 29: 84–89.
19.
WenerMHUwatokoSMannikM. Antibodies to the collagen-like region of C1q in sera of patients with autoimmune rheumatic diseases. Arthritis Rheum1989; 32: 544–551.
20.
TsachevaIRadanovaMTodorovaNArgirovaTKishoreU. Detection of autoantibodies against the globular domain of human C1q in the sera of systemic lupus erythematosus patients. Mol Immunol2007; 44: 2147–2151.
21.
TrendelenburgMLopez-TrascasaMPotlukovaE. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant2006; 21: 3115–3121.
22.
HeidenreichUMayerGHeroldM. Sensitivity and specificity of autoantibody tests in the differential diagnosis of lupus nephritis. Lupus2009; 18: 1276–1280.
23.
MeyerOCNicaise-RolandPCadoudalN. Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther2009; 11: R87–R87.
24.
CaiXYangXLianF. Correlation between serum anti-C1q antibody levels and renal pathological characteristics and prognostic significance of anti-C1q antibody in lupus nephritis. J Rheumatol2010; 37: 759–765.
25.
AkhterEBurlingameRWSeamanALMagderLPetriM. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus2011; 20: 1267–1274.
26.
JulkunenHEkblom-KullbergSMiettinenA. Nonrenal and renal activity of systemic lupus erythematosus: A comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol Int2012; 32: 2445–2451.
de LisoFMatinatoCNovembrinoC. Value of a commercial kit for detecting anti-C1q autoantibodies and correlation with immunological and clinical activity of lupus nephritis. Clin Chem Lab Med2015; 53: 1771–1777.
29.
MannikMWenerMH. Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum1997; 40: 1504–1511.
30.
FranchinGSonMKimSJBen-ZviIZhangJDiamond. Anti-DNA antibodies cross-react with C1q. J Autoimmun2013; 44: 34–39.
31.
TrouwLAGroeneveldTWSeelenMA. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest2004; 114: 679–688.
32.
SiegertCEDahaMRSwaakAJvan der VoortEABreedveldFC. The relationship between serum titers of autoantibodies to C1q and age in the general population and in patients with systemic lupus erythematosus. Clin Immunol Immunopathol1993; 67: 204–209.
33.
WisnieskiJJBaerANChristensenJ. Hypocomplementemic urticarial vasculitis syndrome. Clinical and serologic findings in 18 patients. Medicine (Baltimore)1995; 74: 24–41.
34.
WisnieskiJJNaffGB. Serum IgG antibodies to C1q in hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum1989; 32: 1119–1127.
35.
SiegertCEDahaMRHalmaCvan der VoortEABreedveldFC. IgG and IgA autoantibodies to C1q in systemic and renal diseases. Clin Exp Rheumatol1992; 10: 19–23.
36.
SinicoRARadiceAIkehataM. Anti-C1q autoantibodies in lupus nephritis: Prevalence and clinical significance. Ann N Y Acad Sci2005; 1050: 193–200.
37.
OrbaiA-MTruedssonLSturfeltG. Anti-C1q antibodies in systemic lupus erythematosus. Lupus2015; 24: 42–49.
38.
SaadounDSadallahSTrendelenburgM. Anti-C1q antibodies in hepatitis C virus infection. Clin Exp Immunol2006; 145: 308–312.
39.
WenerMHMannikMSchwartzMMLewisEJ. Relationship between renal pathology and the size of circulating immune complexes in patients with systemic lupus erythematosus. Medicine (Baltimore)1987; 66: 85–97.
40.
SiegertCDahaMWestedtMLvan der VoortEBreedveldF. IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J Rheumatol1991; 18: 230–234.
41.
HaseleyLAWisnieskiJJDenburgMR. Antibodies to C1q in systemic lupus erythematosus: Characteristics and relation to Fc gamma RIIA alleles. Kidney Int1997; 52: 1375–1380.
42.
SjöholmAGMårtenssonUSturfeltG. Serial analysis of autoantibody responses to the collagen-like region of Clq, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus. J Rheumatol1997; 24: 871–878.
43.
MartoNBertolacciniMLCalabuigEHughesGRKhamashtaMA. Anti-C1q antibodies in nephritis: Correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis2005; 64: 444–448.
44.
MoroniGTrendelenburgMDel PapaN. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis2001; 37: 490–498.
45.
TrendelenburgMMarfurtJGerberITyndallASchifferliJA. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum1999; 42: 187–188.
46.
HaddonDJDiepVKPriceJVLimbCUtzPJBalboniI. Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus. Arthritis Res Ther2015; 17: 162–162.
47.
CoremansIESpronkPEBootsmaH. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis1995; 26: 595–601.
48.
BockMHeijnenITrendelenburgM. Anti-C1q antibodies as a follow-up marker in SLE patients. PloS One2015; 10: e0123572–e0123572.
49.
Frémeaux-BacchiVNoëlLHSchifferliJA. No lupus nephritis in the absence of antiC1q autoantibodies?Nephrol Dial Transplant2002; 17: 2041–2043.
50.
GunnarssonISundelinBHeimbürgerM. Repeated renal biopsy in proliferative lupus nephritis—predictive role of serum C1q and albuminuria. J Rheumatol2002; 29: 693–699.
51.
SiegertCEDahaMRTsengCMCoremansIEvan EsLABreedveldFC. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis1993; 52: 851–856.
52.
SiegertCEKazatchkineMDSjöholmAWürznerRLoosMDahaMR. Autoantibodies against C1q: View on clinical relevance and pathogenic role. Clin Exp Immunol1999; 116: 4–8.
53.
MoroniGQuagliniSRadiceA. The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. J Immunol Res2015; 2015: 106904–106904.
